Reaction
Clear Cell Renal Cell Carcinoma reporting signals
As of the last recalculation, Clear Cell Renal Cell Carcinoma appears in 676 FAERS reports alongside 20 co-occurring drug terms. The strongest observed disproportionality signal is TESTOSTERONE (PRR 71.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Testosterone | 50 | 71.0 | 71.2 |
| Anakinra | 27 | 52.2 | 52.2 |
| Azathioprine | 111 | 46.2 | 46.3 |
| Axitinib | 27 | 44.4 | 44.5 |
| Everolimus Tablets | 20 | 37.8 | 37.9 |
| Pazopanib Hydrochloride | 30 | 35.7 | 35.7 |
| Enalapril | 54 | 32.4 | 32.4 |
| Enalapril Maleate | 24 | 30.9 | 30.9 |
| Basiliximab | 11 | 29.3 | 29.3 |
| Medroxyprogesterone Acetate | 36 | 23.4 | 23.5 |
| Lithium | 18 | 22.6 | 22.6 |
| Lithium Bromatum | 18 | 22.6 | 22.6 |
| Sunitinib Malate | 24 | 19.4 | 19.5 |
| Anti-Thymocyte Globulin (Rabbit) | 5 | 19.2 | 19.2 |
| Everolimus | 26 | 16.3 | 16.3 |
| Bendamustine Hcl | 8 | 16.1 | 16.1 |
| Insulin Human | 20 | 15.9 | 15.9 |
| Cabozantinib | 24 | 15.9 | 15.9 |
| Ranitidine | 67 | 11.4 | 11.4 |
| Aflibercept | 6 | 6.0 | 6.0 |